|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||87.36 - 88.54|
|52-week range||57.17 - 89.10|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||33.25|
|Earnings date||30 Jan 2023 - 03 Feb 2023|
|Forward dividend & yield||2.92 (3.32%)|
|Ex-dividend date||14 Dec 2022|
|1y target est||82.71|
SANTA MONICA, Calif. & TOKYO, December 08, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have no
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog.